Laboratory Monitoring: A Turning Point in the Use of New Oral Anticoagulants

Therapeutic Drug Monitoring

Volumn 38, Issue 1, 2016, Pages 12-21

  Scridon, Alina ^a   Serban, Razvan C ^a,b  

^a UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Institute of Cardiovascular Diseases and Transplantation   (Romania)

Author keywords

anticoagulant drugs; direct thrombin inhibitors; Drug monitoring; factor Xa inhibitors; warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K;

ACTIVATED CLOTTING TIME; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; CHROMOGENIC ASSAY; CHRONIC KIDNEY DISEASE; DILUTED THROMBIN TIME; DRUG EFFICACY; DRUG MONITORING; FOOD DRUG INTERACTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LIQUID CHROMATOGRAPHY; MEDICATION COMPLIANCE; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTHROMBIN TIME; TANDEM MASS SPECTROMETRY; THROMBIN TIME; THROMBOEMBOLISM; THROMBOSIS PREVENTION; DRUG INTERACTION; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DRUG INTERACTIONS; DRUG MONITORING; FOOD-DRUG INTERACTIONS; HUMANS; MEDICATION ADHERENCE; THROMBOEMBOLISM;

EID: 84955739198     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000247     Document Type: Article

References (68)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
2. Favaloro EJ, Lippi G, Franchini M. Coagulopathies and thrombosis: usual and unusual causes and associations, part III. Semin Thromb Hemost. 2010;36:1-5.
3. Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost. 2008;34:747-761.
4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
5. Avorn J. The relative cost-effectiveness of anticoagulants: obvious, except for the cost and the effectiveness. Circulation. 2011;123:2519-2521.
6. Nydegger UE, Gygax E, Carrel T. Point-of-care testing in the cardiovascular operating theatre. Clin Chem Lab Med. 2006;44:1060-1065.
7. Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J Thromb Haemost. 2013;11:390-394.
8. Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. J Thromb Haemost. 2010;8:621-626.
9. Favaloro EJ, Lippi G, Adcock DM. Preanalytical and postanalytical variables: the leading causes of diagnostic error in haemostasis? Semin Thromb Hemost. 2008;34:612-634.
10. Perret-Guillaume C, Wahl DG. Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose-A meta-analysis. Thromb Haemost. 2004;91:394-402.
11. Li-Saw-Hee FL, Blann AD, Lip G. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke. 2000;31:828-833.
12. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrium fibrillation. N Engl J Med. 2009;361:1139-1151.
13. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrilation. N Engl J Med. 2011;365:883-891.
14. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
15. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361:2342-2352. EINSTEIN-PE Investigators
16. Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287-1297. EINSTEIN Investigators,
17. Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363:2499-2510.
18. Ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J. 2013;11:8.
19. Garcia D, Barrett YC, Ramacciotti E, et al. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost. 2013;11:245-252.
20. Baglin T, Hillarp A, Tripodi A, et al. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756-760.
21. Olesen JB, Lip GYH, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367: 625-635.
22. Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) and ATRIA (AnTicoagulation and Risk factors in Atrial fibrillation) study cohorts. Circulation. 2013;127:224-232.
23. Camm AJ, Savelieva I. "R" for "renal" and for "risk": refining risk stratification for stroke in atrial fibrillation. Circulation. 2013;127:169-171.
24. Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:47-59.
25. Beasley BN, Unger EF, Temple R. Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364:1788-1790.
26. Hernandez I, Baik SH, Piñera A, et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175:18-24.
27. Perzborn E, Roehrig S, Straub A, et al. The discovery and development of rivaroxaban, an oral direct factor Xa inhibitor. Nat Rev Drug Discov. 2011;10:61-75.
28. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74-81.
29. Mismetti P, Laporte S. Dabigatran: clinical pharmacology. Ann Fr Anesth Reanim. 2009;28:S8-S14.
30. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9:2168-2275.
31. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34:2094-2106.
32. Gnoth MJ, Buetehorn U, Muenster U, et al. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011;338:372-380.
33. Stangier J, Rathgen K, Stahle H, et al. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs. 2009;9:59-68.
34. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386-399.
35. Liesenfeld KH, Schäfer HG, Trocóniz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006;62:527-537.
36. Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther. 2007;45: 335-344.
37. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75:476-487.
38. Pradaxa Product Monograph, Revised 2015. Available at: http://www. boehringeringelheim.ca/content/dam/internet/opu/ca-EN/documents/humanhealth/product-monograph/Pradax-pm.pdf. Accessed October 1, 2015.
39. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005; 45:555-563.
40. Freyburger G, Macouillard G, Labrouche S, et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res. 2011;127:457-465.
41. Kimmel SE, Chen Z, Price M, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) study. Arch Intern Med. 2007;167:229-235.
42. Waterman AD, Milligan PE, Bayer L, et al. Effect of warfarin nonadherence on control of the international normalized ratio. Am J Health Syst Pharm. 2004;61:1258-1264.
43. Choudhry NK, Saya UY, Shrank WH, et al. Cost-related medication underuse: prevalence among hospitalized managed care patients. J Hosp Med. 2012;7:104-109.
44. Lindahl TL, Baghaei F, Blixter IG, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105:371-378.
45. Favaloro EJ, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb). 2012;22: 329-341.
46. Halbmayer WM, Weigel G, Quehenberger P, et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med. 2012;50:1601-1605.
47. Samama MM, Contant G, Spiro TE, et al. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost. 2012;18:150-158.
48. Dager WE, Gosselin RC, Kitchen S, et al. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother. 2012;46:1627-1636.
49. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103:815-825.
50. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:141S-159S.
51. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103:1116-1127.
52. Tripodi A, Chantarangkul V, Guinet C, et al. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost. 2011;9:226-228.
53. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011;9:133-139.
54. Mitchell LG, Dietrich K, Stang L, et al. Comparison of Hemoclot to standard coagulation assays for monitoring the direct thrombin inhibitor (dabigatran) in pediatric patients: an in vitro study. J Thromb Haemost. 2009;7:777; Abstract PP-WE-448.
55. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb. 2003;33:173-183.
56. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292-303.
57. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008; 47:285-295.
58. Adcock DM, Gosselin R, Kitchen S, et al. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol. 2013;139: 102-109.
59. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365: 699-708.
60. Asmis LM, Alberio L, Angelillo-Scherrer A, et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res. 2012;129:492-498.
61. Becker RC, Yang H, Barrett Y, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011; 32:183-187.
62. Eby C. Novel anticoagulants and laboratory testing. Int J Lab Hematol. 2013;35:262-268.
63. Delavenne X, Mismetti P, Basset T. Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J Pharm Biomed Anal. 2013;78-79:150-153.
64. Ţ ilea I, Popa DS, Szakács Xantus T, et al. Determination of apixaban levels in human plasma by a high-throughput liquid chromatographic tandem mass spectrometry assay. Rev Romana Med Lab. 2015;23:115-126.
65. Rohde G. Determination of rivaroxaban-A novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatographytandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;872:43-50.
66. Artang R, Galloway G, Nielsen JD. Monitoring novel anticoagulants dabigatran, rivaroxaban and apixaban using thrombelastography. J Am Coll Cardiol. 2014;63:A439.
67. Gous T, Couchman L, Patel JP, et al. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit. 2014;36: 597-605.
68. Frost C, Song Y, Barrett YC, et al. Direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. J Thromb Haemost. 2011;9:569; Abstract P-WE-159.